(Bloomberg) — Actavis P.L.C. was ordered to continue to provide the immediate-release version of its Namenda Alzheimer’s drug in a win for New York Attorney General Eric Schneiderman, who sued the company in September.
The Dublin-based company confirmed in a statement today that U.S. District Judge Robert Sweet in Manhattan intends to issue a preliminary injunction in the antitrust case requiring it to continue distributing the immediate-release tablets. The ruling was filed under seal.
Schneiderman sued Actavis Sept. 15, alleging the drugmaker was “gaming” the system by discontinuing the immediate-release drug, which is facing competition from generic versions as the patent expires next year, and forcing patients to switch to the extended-release drug, which has longer-running patents.